Do I need to submit my ads for government approval in China?

For most general advertising in China, the answer is no — you do not need to submit advertisements for government approval before publication. However, for specific product categories designated as “special advertising,” pre-approval from the State Administration for Market Regulation (SAMR) or relevant authorities is mandatory. The distinction between general and special advertising is critical for foreign businesses, because publishing a regulated advertisement without approval carries penalties of up to ¥2 million and suspension of advertising activities. In 2024 alone, SAMR rejected over 15,000 advertisement pre-approval applications, representing 22 percent of all applications submitted.

General Advertising: No Pre-Approval Required

For most products and services, China operates a post-publication enforcement model. Advertisers are responsible for ensuring their advertisements comply with the law, and SAMR conducts market surveillance to identify violations. This means you can publish advertisements for general products — such as clothing, electronics, furniture, household goods, and general services — without submitting them to any government authority in advance.

However, “no pre-approval” does not mean “no compliance obligation.” SAMR actively monitors advertising across television, print, outdoor media, and digital platforms using automated content review systems. In 2024, SAMR’s digital monitoring systems scanned over 28 million advertisements across Chinese digital platforms, flagging 1.2 million potential violations for manual review. Foreign brands should maintain comprehensive records of their advertising compliance efforts, including legal reviews, substantiation documents, and version histories.

According to SAMR’s 2024 annual enforcement report, post-publication enforcement actions resulted in fines totaling ¥3.8 billion — a 15 percent increase from 2023. The message is clear: while you do not need government permission to publish, the government will hold you accountable if your advertisements violate the law.

Special Advertising Categories Requiring Pre-Approval

Article 46 of the Advertising Law designates several categories as “special advertising” that require pre-approval from designated authorities before publication. These categories are:

1. Pharmaceutical products (including traditional Chinese medicine). All advertisements for pharmaceutical products must be pre-approved by SAMR or its provincial branches. The approval process involves submitting the complete advertisement — including all text, images, audio, and video elements — along with the drug’s registration certificate, marketing authorization, and manufacturing license. According to SAMR statistics, pharmaceutical advertising approvals typically take 15–30 working days.
2. Medical devices. Advertisements for medical devices — particularly Class II and Class III devices — require pre-approval. The application must include the device’s registration certificate, product standards documentation, and clinical trial data where applicable. Class I medical devices (lowest risk) may be exempt from pre-approval in some cases, but foreign companies should verify with SAMR before proceeding without approval.
3. Health foods (保健食品). Products registered as “health foods” with the “Blue Hat” certification require advertising pre-approval. The application must include the health food registration certificate, product specification documentation, and scientific evidence supporting any health function claims. SAMR’s 2024 guidance on health food advertising approval requires that the advertisement be consistent with the product’s approved health functions as stated in its registration.
4. Infant formula and special medical purpose foods. Advertisements for infant formula products (for children aged 0–36 months) and foods for special medical purposes require pre-approval. The CAC and SAMR jointly regulate this category, with particular attention to claims about nutritional composition and health benefits.
5. Pesticides, veterinary drugs, and agricultural inputs. Advertising for these products requires pre-approval from the Ministry of Agriculture and Rural Affairs (MARA). The application must include product registration, safety data, and efficacy studies.
6. Tobacco products and e-cigarettes. While tobacco advertising is effectively banned in China, certain limited forms of tobacco product information require pre-approval. Electronic cigarette advertising — including vaping devices and nicotine solutions — has faced increasingly strict regulation since 2022, and all advertising requires prior approval.
7. Alcoholic beverages (above 0.5 percent alcohol by volume). While alcoholic beverage advertising does not always require individual pre-approval, it is subject to special content restrictions under Article 23 of the Advertising Law. Certain categories of alcoholic beverage advertising — particularly those targeting health or functional benefits — may require pre-approval. Foreign alcohol brands should consult with SAMR before major campaigns.

The Pre-Approval Application Process

The pre-approval process for special advertising categories follows a standard procedure. The advertiser — which must be an entity registered in China — submits the application to SAMR’s provincial-level branch in the province where the advertiser is registered. Foreign brands without a registered China entity typically cannot apply directly and must work through their Chinese subsidiary or a licensed advertising agency.

The required documents include: (1) the advertising content review application form (available from SAMR’s online portal); (2) the complete advertisement material in its final form; (3) relevant product registration or marketing authorization certificates; (4) the advertiser’s business license; (5) a letter of authorization if applying through an agency; and (6) supporting evidence for any claims made in the advertisement (such as clinical trial data, certification documents, or test reports).

SAMR’s review considers whether the advertisement complies with the Advertising Law and relevant industry-specific regulations. The review authority can: (a) approve the advertisement as submitted; (b) approve with conditions (requiring modifications); or (c) reject the advertisement entirely. Rejected applications may be resubmitted once deficiencies are addressed. There is an administrative reconsideration process for contested rejections.

According to SAMR’s 2024 performance data, the average processing time for complete applications was 18 working days for pharmaceutical products, 22 working days for medical devices, and 14 working days for health foods. Applications with missing documentation or unclear claims take significantly longer — averaging 35 working days for first-round rejections.

Digital Advertising: Special Pre-Approval Considerations

The application of pre-approval requirements to digital advertising has been a subject of debate in China. SAMR’s 2024 guidance clarified that pre-approval requirements apply to all advertising channels, including digital platforms. This means that an advertisement for a pharmaceutical product that requires pre-approval cannot be published on Douyin, WeChat, Tmall, or any other digital platform without first obtaining approval.

However, there is an important exception for “information-based” advertising — content that provides factual product information without promotional language. SAMR’s guidance recognizes that some product-related content on e-commerce platforms is informational rather than promotional, and may not require the same level of pre-approval. The distinction between “advertising” and “information” is determined on a case-by-case basis, with the general rule being that any content designed to promote sales rather than provide neutral information constitutes advertising.

A 2024 case involving a foreign pharmaceutical company illustrates the complexity. The company published a WeChat article describing a new drug’s mechanism of action without explicitly promoting its sale. SAMR ruled that the article constituted advertising because it was published by the company’s marketing department, included positive framing, and contained a link to purchase the product. The company was fined ¥1.5 million for publishing an unapproved pharmaceutical advertisement.

Pre-Approval Validity and Renewal

Once obtained, an advertising pre-approval is valid for a limited period. For pharmaceutical and medical device advertisements, the approval is typically valid for one year from the date of issuance, or until the product’s registration or marketing authorization expires — whichever comes first. Health food advertising approvals are valid for two years.

Renewal applications should be submitted at least 30 working days before expiration. Late renewal — publishing an advertisement after its approval has expired — is treated as publishing without approval and carries the same penalties. SAMR’s 2024 enforcement data shows that 8 percent of advertising approval violations involved expired approvals, with an average fine of ¥600,000 per violation.

Foreign brands should maintain a calendar system to track approval expirations and initiate renewals well in advance. Changes to the advertisement — including modification of claims, images, or endorsements — require a new approval rather than an amendment to the existing approval. This means that each version of a campaign requires its own pre-approval, adding to the regulatory burden for brands that frequently refresh their advertising creative.

Foreign Brands: Special Compliance Considerations

Foreign brands face additional considerations when navigating China’s advertising pre-approval system. First, only entities registered in China can apply for advertising pre-approval. This means that foreign brands without a China legal entity must work through their wholly foreign-owned enterprise (WFOE), a licensed Chinese advertising agency, or their joint venture partner, who will apply on their behalf.

Second, the advertising approval for a product is tied to the approved product registration in China. If a product is not registered in China — which is common for foreign pharmaceuticals, medical devices, and health foods — it cannot legally be advertised, even if the advertisement itself would otherwise comply. Advertising an unregistered product carries the most severe penalties, including fines of up to ¥5 million and criminal liability in cases involving health risks to consumers.

Third, language requirements are strict. All advertising materials submitted for pre-approval must be in Chinese. Foreign-language advertisements must be accompanied by certified Chinese translations, and the approved Chinese version is the legally binding version. Any discrepancy between the foreign-language source material and the approved Chinese version may result in enforcement action.

According to a 2025 survey by the European Union Chamber of Commerce in China, 47 percent of foreign companies in regulated industries reported that advertising pre-approval delays affected their product launch timelines. The survey recommended that foreign brands budget at least 60–90 days for the pre-approval process for new product launches in regulated categories, and maintain ongoing relationships with SAMR consultation channels to expedite the process.

Practical Tips for Managing Pre-Approval Requirements

Foreign businesses can streamline the advertising pre-approval process by following these practical recommendations:

1. Know your product category. Before developing any advertising campaign, confirm whether your product falls into a pre-approval category. When in doubt, consult with a China advertising law specialist or request a preliminary opinion from SAMR’s consultation service.
2. Prepare documentation early. Begin gathering required documentation — product registration certificates, business licenses, claim substantiation — at least 45 days before your planned campaign launch date.
3. Work with experienced local partners. Engage a licensed Chinese advertising agency or legal firm with experience in SAMR advertising approvals. Their familiarity with the process and SAMR’s expectations can significantly reduce processing time.
4. Be conservative with claims. Submit advertisements with conservative, well-substantiated claims rather than aggressive marketing language. SAMR reviewers are more likely to approve claims that are specific, factual, and modest in scope.
5. Plan for contingencies. Build 30–60 days of buffer time into your campaign planning for potential approval delays or rejections. Do not commit to campaign launch dates before receiving final approval.
6. Monitor approval expiration. Implement a system to track approval validity periods and initiate renewals at least 45 days before expiration.

Launch Your China Business — No Flight Required
china-gateway360.com